Payment overview · 2025
General Payments
$173.17
9 reported records · 7 companies
Healthcare provider profile · identity verified
Caleb Robert Overpeck, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DALEVILLE, IN · NPI 1740576529
Verified facts
What the public records show
CMS Open Payments records show Caleb Robert Overpeck, M.D. received $173.17 in general payments during 2025 across 9 reported records.
PFIZER INC. accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.96 | 23.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.94 | 17.3% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $27.49 | 15.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.35 | 12.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.99 | 11.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.30 | 10.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.14 | 9.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $173.17 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.94 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $27.49 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.59 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $26.59 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 14 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 95 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
60 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
89 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
121 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
95 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 613 | 189 |
| Levothyroxine Sodium | Levothyroxine Sodium | 343 | 95 |
| Lisinopril | Lisinopril | 309 | 106 |
| Gabapentin | Gabapentin | 279 | 76 |
| Omeprazole | Omeprazole | 269 | 84 |
| Metformin Hcl | Metformin Hcl | 244 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 240 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 240 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 221 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 167 | 41 |
| Mounjaro | Tirzepatide | 147 | 32 |
| Losartan Potassium | Losartan Potassium | 131 | 48 |
| Montelukast Sodium | Montelukast Sodium | 125 | 37 |
| Ozempic | Semaglutide | 121 | 27 |
| Pregabalin | Pregabalin | 119 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 48 |
| Farxiga | Dapagliflozin Propanediol | 104 | 25 |
| Trazodone Hcl | Trazodone Hcl | 104 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 45 |
| Allopurinol | Allopurinol | 102 | 30 |
| Sertraline Hcl | Sertraline Hcl | 101 | 28 |
| Prednisone | Prednisone | 99 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 98 | 32 |
| Carvedilol | Carvedilol | 97 | 28 |
| Furosemide | Furosemide | 97 | 36 |
| Eliquis | Apixaban | 95 | 25 |
| Linzess | Linaclotide | 95 | 14 |
| Meloxicam | Meloxicam | 95 | 33 |
| Alendronate Sodium | Alendronate Sodium | 92 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 26 |
| Jardiance | Empagliflozin | 88 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 28 |
| Bupropion Xl | Bupropion Hcl | 75 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 26 |
| Tramadol Hcl | Tramadol Hcl | 73 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 19 |
| Celecoxib | Celecoxib | 67 | 14 |
| Alprazolam | Alprazolam | 66 | 14 |
| Simvastatin | Simvastatin | 66 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 20 |
| Potassium Chloride | Potassium Chloride | 64 | 23 |
| Ibuprofen | Ibuprofen | 63 | 19 |
| Topiramate | Topiramate | 61 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 60 | 51 |
| Ezetimibe | Ezetimibe | 59 | 16 |
| Torsemide | Torsemide | 59 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 21 |
| Buspirone Hcl | Buspirone Hcl | 57 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 15 |
| Famotidine | Famotidine | 53 | 13 |
| Methylprednisolone | Methylprednisolone | 52 | 43 |
| Azithromycin | Azithromycin | 51 | 37 |
| Aripiprazole | Aripiprazole | 48 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 34 |
| Divalproex Sodium | Divalproex Sodium | 46 | suppressed |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Diazepam | Diazepam | 43 | 13 |
| Metformin Hcl Er | Metformin Hcl | 43 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 40 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 12 |
| Trulicity | Dulaglutide | 36 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 15 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Naproxen | Naproxen | 30 | 11 |
| Ondansetron Odt | Ondansetron | 29 | 15 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | 13 |
| Finasteride | Finasteride | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 20 |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 16 |
| Primidone | Primidone | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 20 | suppressed |
| Nystatin | Nystatin | 20 | 12 |
| Cefdinir | Cefdinir | 19 | 16 |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 14 |
| Enulose | Lactulose | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Cabergoline | Cabergoline | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Atenolol | Atenolol | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $173.17 · 9 records | PFIZER INC. | ABRYSVO, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, ENFLONSIA, GARDASIL 9, NURTEC ODT, PREVNAR 20, PROQUAD, SAPIEN 3 Ultra RESILIA, SHINGRIX, VAXNEUVANCE, WATCHMAN FLX, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error